Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
289.20
-2.57 (-0.88%)
Aug 18, 2026, 10:02 AM EDT - Market open
Ligand Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 197.22 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Depreciation & Amortization | 32.91 | 33.78 | 35.24 | 36.52 | 38.32 | 50.95 |
Other Amortization | 4.56 | 3.22 | 2.61 | 1.98 | 6.26 | 21.53 |
Loss (Gain) From Sale of Assets | - | - | - | -2.12 | - | - |
Asset Writedown & Restructuring Costs | 6.2 | 6.2 | 30.57 | 0.92 | - | - |
Loss (Gain) From Sale of Investments | -181.78 | -167.13 | -34.63 | -47.68 | -28.52 | 4.11 |
Loss (Gain) on Equity Investments | - | - | 7.01 | 1.83 | - | - |
Stock-Based Compensation | 53.27 | 46.85 | 41.09 | 25.74 | 50.88 | 38.78 |
Other Operating Activities | 21.78 | 14.67 | -0.17 | 14.64 | 16.54 | -36.71 |
Change in Accounts Receivable | -25.84 | -21.74 | -6.46 | -2.6 | 55.32 | -28.62 |
Change in Inventory | 5.23 | 4.99 | 9.62 | -10.87 | 12.06 | -0.43 |
Change in Accounts Payable | 14.4 | 5.88 | 13.9 | -4.7 | -3.34 | 2.81 |
Change in Unearned Revenue | - | -0.58 | -1.31 | 0.42 | -6.28 | -17.87 |
Change in Income Taxes | 0.43 | 2.67 | 2.31 | -1.78 | 1.58 | -3.98 |
Change in Other Net Operating Assets | 3.34 | -3.89 | 1.29 | -14.87 | 6.34 | -8.93 |
Operating Cash Flow | 131.71 | 49.36 | 97.05 | 49.58 | 137.85 | 78.8 |
Operating Cash Flow Growth | 137.94% | -49.14% | 95.75% | -64.04% | 74.94% | 44.36% |
Capital Expenditures | -0.28 | -0.45 | -1.82 | -3.52 | -12.35 | -8.76 |
Cash Acquisitions | - | - | - | -10.41 | - | - |
Divestitures | -8.09 | -8.09 | - | - | - | - |
Sale (Purchase) of Intangibles | - | - | - | - | - | 0.49 |
Investment in Securities | -126.86 | -349.73 | -136.08 | 52.15 | 182.42 | 40.01 |
Other Investing Activities | -9.56 | -19.05 | -5.77 | -49.91 | -6.44 | -1.22 |
Investing Cash Flow | -144.78 | -377.32 | -143.66 | -11.68 | 163.62 | 30.52 |
Long-Term Debt Issued | - | 460 | - | - | - | - |
Long-Term Debt Repaid | - | -113.28 | -0.03 | -76.9 | -261 | -164.95 |
Net Debt Issued (Repaid) | 850.93 | 346.72 | -0.03 | -76.9 | -261 | -164.95 |
Issuance of Common Stock | 51.3 | 47.5 | 102.73 | 22.45 | 3.23 | 33.76 |
Repurchase of Common Stock | -97.64 | -24.6 | -5.14 | -4.55 | -8.24 | -6.02 |
Other Financing Activities | 145.69 | 58.6 | -0.43 | -0.95 | -9.98 | -0.56 |
Financing Cash Flow | 950.28 | 428.22 | 97.14 | -59.95 | -275.99 | -137.76 |
Foreign Exchange Rate Adjustments | -1 | 2.36 | -1.17 | - | - | - |
Net Cash Flow | 939.03 | 102.62 | 49.35 | -22.05 | 25.48 | -28.44 |
Free Cash Flow | 131.44 | 48.91 | 95.23 | 46.06 | 125.5 | 70.04 |
Free Cash Flow Growth | 145.13% | -48.64% | 106.76% | -63.30% | 79.19% | 39.72% |
Free Cash Flow Margin | 45.24% | 18.24% | 56.98% | 35.07% | 63.95% | 29.00% |
Free Cash Flow Per Share | 6.13 | 2.41 | 5.21 | 2.59 | 7.44 | 4.06 |
Levered Free Cash Flow | 139.75 | 87.09 | 100.79 | 46.03 | 136.93 | 37.03 |
Unlevered Free Cash Flow | 140.98 | 88.76 | 102.2 | 46.2 | 137.33 | 32.6 |
Cash Interest Paid | 2.49 | 0.32 | 0.26 | 0.29 | 1.43 | 3.03 |
Cash Income Tax Paid | 6.56 | 7.8 | 19.21 | 8.77 | 11.64 | 3.72 |
Change in Working Capital | -2.44 | -12.67 | 19.36 | -34.4 | 65.68 | -57 |